ANSWERS TO YOUR
QUESTIONS
ABOUT
AOSD AND ILARIS

What is AOSD?

Adult-Onset Still's Disease (AOSD) is a rare autoinflammatory disease which can be caused by having too much of or being too sensitive to certain proteins, including IL-1β, and can lead to symptoms such as fever, rash, headache, feeling very tired (fatigue), or painful joints and muscles. AOSD is a type of Still's disease.

What causes AOSD?

AOSD is an idiopathic disease, which means that its cause is unknown. What is known about AOSD is that it's a rare autoinflammatory disease, meaning that it causes the body's immune system to attack healthy cells, leading to the signs and symptoms of AOSD.

How long will I have AOSD?

It can vary. You may need to undergo AOSD treatment for a period of several years or more. But with treatment, patients with AOSD can experience symptom improvement as time passes.

What is the difference between a localized and a systemic symptom?

As opposed to localized symptoms, such as pain in certain joints, systemic symptoms can affect the body as a whole. For example, a systemic symptom of AOSD is fever.

What will happen to me with AOSD?

AOSD affects everyone differently. The disease cycle swings back and forth between symptom-free periods and flares, or times when the symptoms worsen. Some patients with AOSD only get one cycle of symptoms, and others will have a chronic course of ups and downs. Learn about AOSD treatment options.

What is ILARIS?

ILARIS^® is a prescription medication that is FDA approved to treat Still's disease, including AOSD in adults. ILARIS works by attaching to and blocking interleukin-1 beta (IL-1β), a type of cytokine responsible for inflammation. For AOSD, ILARIS is given once a month as a subcutaneous injection right below the skin.

How can ILARIS help with active AOSD?

ILARIS can help relieve AOSD symptoms. FDA approval for AOSD was based on established efficacy of ILARIS in SJIA patients and evaluations of clinical data of AOSD and SJIA patients. In an SJIA study, ILARIS helped relieve SJIA symptoms including fevers (systemic) and painful and/or swollen joints (arthritic). In addition, some SJIA patients receiving ILARIS were able to reduce or stop taking corticosteroids altogether. For AOSD, ILARIS is given by a doctor or nurse as a once-monthly injection right below the skin. Talk to your doctor to find out if ILARIS may be a treatment option for you.

How fast does ILARIS work?

FDA approval for AOSD was based on established efficacy of ILARIS in SJIA patients and evaluations of clinical data of AOSD and SJIA patients. 190 children were entered into SJIA clinical studies to determine the impact of ILARIS on SJIA symptoms. Fifteen days after their first dose of ILARIS, approximately 8 out of 10 children taking ILARIS experienced improvement in active SJIA symptoms, such as fever and painful and/or swollen joints. None of the children taking ILARIS had fever by day 3 after the first dose.

Is ILARIS given intravenously?

ILARIS is not given as an intravenous infusion (infused inside a vein over a period of time). Instead, it is given as a subcutaneous (right under the skin) injection, or shot, by a doctor or nurse.

How often will I receive ILARIS?

For AOSD, ILARIS is given as a once-monthly injection. A home health nurse can be sent to your home to administer ILARIS. If you are eligible, this service and other ILARIS support options may be available for you.

Is support available to help me pay for ILARIS?

We're committed to helping you get access to ILARIS. Our ILARIS Companion representatives are here to help by working with your doctor, and:

Contacting your insurance company
Verifying insurance benefits and investigation of coverage
Addressing coverage issues
Navigating prior authorization and appeals, if needed
Providing co-pay* assistance for eligible patients with commercial insurance
Providing information about alternative assistance options for uninsured patients

*Limitations apply. Please contact ILARIS Companion at 866-972-8315 for more information.

Whom should I speak to if I have more questions about ILARIS?

Talk to your rheumatologist or other healthcare professional. Your active AOSD treatment team can consist of many important members. Make sure that you find a doctor that you are comfortable with.

Next: AOSD Glossary

11/23 307063

More +

Less -

IMPORTANT SAFETY INFORMATION

ILARIS can cause serious side effects, including increased risk of serious infections. ILARIS can lower the ability of your immune system to fight infections. Your healthcare provider should:

test you for tuberculosis (TB) before you receive ILARIS
monitor you closely for symptoms of TB during treatment with ILARIS
check you for symptoms of any type of infection before, during, and after treatment with ILARIS

Tell your healthcare provider right away if you have any symptoms of an infection such as fever, sweats or chills, cough, flu-like symptoms, weight loss, shortness of breath, blood in your phlegm, sores on your body, warm or painful areas on your body, diarrhea or stomach pain, or feeling very tired.

Do not receive ILARIS if you are allergic to canakinumab or any of the ingredients in ILARIS.

Before receiving ILARIS, tell your healthcare provider about all your medical conditions, including if you:

think you have or are being treated for an active infection
have symptoms of infection
have a history of infections that keep coming back
have a history of low white blood cells
have or have had HIV, Hepatitis B, or Hepatitis C
have recently received or are scheduled to receive any vaccinations
- You should be brought up to date with all age required vaccines before starting treatment with ILARIS
- You should not receive "live" vaccines while you are being treated with ILARIS and until your healthcare provider tells you that your immune system is no longer weakened

APPROVED USE

ILARIS^® (canakinumab) is a prescription medicine injected by your healthcare provider just below the skin (subcutaneous) used to treat:

The following autoinflammatory Periodic Fever Syndromes:
- Cryopyrin-Associated Periodic Syndromes (CAPS) in patients 4 years of age and older, including:
  - Familial Cold Autoinflammatory Syndrome (FCAS)
  - Muckle-Wells Syndrome (MWS)
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
- Hyperimmunoglobulin D Syndrome (HIDS) also known as Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients
- Familial Mediterranean Fever (FMF) in adult and pediatric patients
Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in children 2 years of age and older
Gout flares in adults who:
- are not able to receive or tolerate treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine
- have not responded to treatment with NSAIDs and colchicine
- are not able to receive repeated treatment with steroids

It is not known if ILARIS is safe and effective when used to treat:

SJIA in children under 2 years of age
CAPS in children under 4 years of age
gout flares in children

are pregnant or planning to become pregnant. It is not known if ILARIS will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while receiving ILARIS
received ILARIS while you were pregnant. It is important that you tell your baby's healthcare provider before any vaccinations are given to your baby within 4 to 12 months after you received your last dose of ILARIS before giving birth
are breastfeeding or planning to breastfeed. It is not known if ILARIS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive ILARIS

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:

medicines that affect your immune system
medicines called interleukin-1 (IL-1) blocking agents such as Kineret^® (anakinra) or Arcalyst^® (rilonacept)
medicines called tumor necrosis factor (TNF) inhibitors such as Enbrel^® (etanercept), Humira^® (adalimumab), Remicade^® (infliximab), Simponi^® (golimumab), or Cimzia^® (certolizumab pegol)
medicines that affect enzyme metabolism

Ask your healthcare provider for a list of these medicines if you are not sure.

ILARIS can cause serious side effects including:

serious infections
decreased ability of the body to fight infections (immunosuppression). For people treated with medicines that cause immunosuppression like ILARIS, the chances of getting cancer may increase
allergic reactions. Allergic reactions can happen while receiving ILARIS. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction: difficulty breathing or swallowing, nausea, dizziness or feeling faint, rash, itching or hives, palpitations (feels like your heart is racing), or low blood pressure
risk of infection with live vaccines. You should not get live vaccines if you are receiving ILARIS. Tell your healthcare provider if you are scheduled to receive any vaccines

The most common side effects of ILARIS when used for the treatment of CAPS include: cold symptoms, diarrhea, flu (influenza), runny nose, headache, cough, body aches, nausea, vomiting, and diarrhea (gastroenteritis), feeling like you are spinning (vertigo), weight gain, injection-site reactions (such as redness, swelling, warmth, or itching), and nausea.

The most common side effects of ILARIS when used for the treatment of TRAPS, HIDS/MKD, and FMF include: cold symptoms, upper respiratory tract infection, runny nose, sore throat, nausea, vomiting, and diarrhea (gastroenteritis), and injection-site reactions (such as redness, swelling, warmth, or itching).

The most common side effects of ILARIS when used for the treatment of Still's disease (AOSD and SJIA) include: cold symptoms, upper respiratory tract infection, pneumonia, runny nose, sore throat, urinary tract infection, nausea, vomiting, and diarrhea (gastroenteritis), stomach pain, and injection-site reactions (such as redness, swelling, warmth, or itching).

The most common side effects of ILARIS when used for the treatment of gout flares include: cold symptoms, upper respiratory tract infection, urinary tract infection, increased levels of triglycerides in blood, and back pain.

Tell your healthcare provider about any side effect that bothers you or does not go away.

What is Macrophage Activation Syndrome (MAS)?

MAS is a syndrome associated with Still's disease and some other autoinflammatory diseases like HIDS/MKD that can lead to death. Tell your healthcare provider right away if your AOSD or SJIA symptoms get worse or if you have any of these symptoms of an infection:

a fever lasting longer than 3 days
a cough that does not go away
redness in one part of your body
warm feeling or swelling of your skin

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

All trademarks and registered trademarks are the property of their respective owners.

APPROVED USE

ILARIS^® (canakinumab) is a prescription medicine injected by your healthcare provider just below the skin (subcutaneous) used to treat:

The following auto-inflammatory Periodic Fever Syndromes
- Cryopyrin-Associated Periodic Syndromes (CAPS) in patients 4 years of age and older, including:
  - Familial Cold Autoinflammatory Syndrome (FCAS)
  - Muckle-Wells Syndrome (MWS)
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
- Hyperimmunoglobulin D Syndrome (HIDS) also known as Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients
- Familial Mediterranean Fever (FMF) in adult and pediatric patients
Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in children 2 years of age and older.
Gout flares in adults who:
- are not able to receive or tolerate treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine
- have not responded to treatment with NSAIDs and colchicine
- are not able to receive repeated treatment with steroids

It is not known if ILARIS is safe and effective when used to treat SJIA in children under 2 years of age or when used to treat CAPS in children under 4 years of age or when used to treat gout flares in children.

ANSWERS TO YOUR QUESTIONS ABOUT AOSD AND ILARIS

ANSWERS TO YOUR
QUESTIONS
ABOUT
AOSD AND ILARIS